Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Sierra Oncology

Recap: Sierra Oncology Q1 Earnings

Sierra Oncology (NASDAQ:SRRA) reported its Q1 earnings results on Friday, May 6, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 6, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

Upgrades

Benzinga · Apr 14, 2022

Analyst Ratings for Sierra Oncology

Sierra Oncology (NASDAQ:SRRA) has observed the following analyst ratings within the last quarter:

Benzinga · Apr 14, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers

Benzinga · Apr 13, 2022

Sierra Oncology Stock Is Soaring: Here's Why

Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in cash, representing an a

Benzinga · Apr 13, 2022

GSK buys US-based cancer specialist Sierra Oncology for $1.9 billion

Deal is in step with GSK’s strategy of building a strong portfolio of new specialty medicines and vaccines

Evening Standard · Apr 13, 2022

Sierra Oncology Raises $135M Via Equity To Fund Lead Program Development

Sierra Oncology Inc (NASDAQ: SRRA) has priced its underwritten public offering of 4.07 million shares at $27 per share and the pre-funded warrants at $26.999 per pre-funded warrant.

Benzinga · Jan 27, 2022

Read news from The Economist, FT, and more,
with one subscription

Sierra Oncology Secures Debt Facility Of Up To $125M With Oxford Finance To Support Momelotinib Development

Sierra Oncology Inc (NASDAQ: SRRA) has

Benzinga · Jan 25, 2022

Sierra Oncology Shares Rally As Bone Marrow Cancer Candidate Hits Primary Goal

Sierra Oncology Inc (NASDAQ: SRRA)

Benzinga · Jan 25, 2022

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga · Jan 25, 2022

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.